Tagged with HAL

Pharma Emmanuelle Ribot-Mariotte, general manager of Alfa Wassermann Pharma France, reveals how over the past year the company has been working hard on a new innovative treatment for hepatic encephalopathy, Rifaximin-alpha 500, and why their strategy is to focus on gastro-intestinal diseases, a field which has always been at the heart…

Pharma Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities; how they will look to continue to establish themselves in their three main areas: respiratory diseases,…

Pharma Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by collaborating with Italy’s extensive network of key opinion leaders, as well as his desire to see Santen’s innovative drugs brought…

Pharma Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third largest pharma ophthalmic company in Europe, and the only pan-European ophthalmic company to have its headquarters on the continent, and…

Pharma A well-established player in the Allergy market, the Dutch company HAL Allergy recently expanded its activities with the addition of its HALIX Contract Manufacturing Outsourcing (CMO) arm. CEO Harry Flore highlights how the complete package and Good Manufacturing Practice (GMP) experience offered by HALIX, along with the company’s long-standing in-house…

pharma Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic player across the whole of Europe and why 2015 was a significant year for the group, receiving European marketing approval…

pharma Rikus Wolbers, Director at Novio Tech Campus, a key international incubator for R&D and manufacturing companies who are active at the interface of life sciences and high tech, and John Schalken, Program Director SMB Life Sciences, give an overview of the impressive developments in the Nijmegen area and the potential…

Pharma The CEO and CFO of SkylineDx talk about the company’s latest product, the MMprofiler™, a prognostic test to determine the level of risk of a multiple myeloma. Also discussed are SkylineDx’s future plans and how private funding capital is fostering a renaissance of the Dutch biotech sector. Personalized medicine will improve…

pharma Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the significance of establishing strong partnerships with local industry leaders and how this can effectively drive future success for the company’s…

Pain Latin America continues to be in the spotlight at Grünenthal. The managing director for Mexico explains how the company is strengthening its product portfolio, working with stakeholders to create more awareness about pain treatment and on the good path to hit USD 100 million sales within the next four years.…

mergers The global pharmaceutical sector continues to witness significant mergers and acquisitions activity, with 122 M&A deals completed in 2013. This trend has continued due to several multi-billion dollar deals around the world in 2014, which is already recorded the busiest year for healthcare acquisitions. In Chile, the dealmaking sweeping started in December 2013…

Grünenthal GmbH You have been with Grünenthal since 2004 and as the Austria Country Manager since June 2012. What were your initial goals when you took up the position and how have they panned out so far? I wanted to make a change — a change for patients; a change for those…